Menu Search
Equities

Regeneron Pharmaceuticals Inc

0R2M:LSE

Regeneron Pharmaceuticals Inc

Actions
  • Price (USD)817.80
  • Today's Change0.000 / 0.00%
  • Shares traded1.11k
  • 1 Year change+3.65%
  • Beta--
Data delayed at least 20 minutes, as of Nov 12 2024 19:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

  • Revenue in USD (TTM)13.85bn
  • Net income in USD4.65bn
  • Incorporated1988
  • Employees13.45k
  • Location
    Regeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
  • Phone+1 (781) 370-5000
  • Websitehttps://www.regeneron.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.